Birgit C.P. Koch is a distinguished Hospital Pharmacist-Clinical Pharmacologist and Full Professor of Clinical Pharmacometrics. She plays a pivotal role as the supervisor of the clinical pharmacology residency, the director of research and teaching pharmacy, and a key member of the pharmacy management team.

Her journey in pharmacy began at the University of Utrecht in the Netherlands, where she earned her degree. In 2003, she qualified as a pharmacist and embarked on a residency in Hospital Pharmacy at Meander MC in Amersfoort. This residency was uniquely combined with PhD research, made possible by a research grant from the Dutch Kidney Foundation. Her award-winning thesis, End-stage Renal Disease: Sleep Disturbances and the Biological Clock, was successfully defended at the Vrije Universiteit Amsterdam in September 2009. During the final phase of her PhD, she also pursued an internship in Clinical Pharmacology at VUmc in Amsterdam.

In October 2009, she joined Erasmus MC as a hospital pharmacist, and by October 2011, she assumed the role of Hospital Pharmacist-Clinical Pharmacologist in the Pharmacy Laboratory of Erasmus MC, specializing in Therapeutic Drug Monitoring and Toxicology. Over the years, she has held numerous leadership positions, including serving as president of VENA (Female Academic Network Rotterdam) and as a board member of the Dutch Knowledge Center on Pregnancy-related Psychiatry.

Currently, she is actively engaged in various professional and scientific organizations. She serves as a member of the executive board of EPASG, the PK/PD group of ESCMID, and holds leadership roles in IATDMCT, including director of education and council member. Additionally, she contributes to the pharmacology committee of UEMS, the specialist registration committee for hospital pharmacists and clinical pharmacologists in the Netherlands, and several other prestigious groups such as ISAP, ASCPT, EACPT, SWAB, and the medical ethical board. She is also an editorial board member of Therapeutic Drug Monitoring, British Journal of Clinical Pharmacology, and Clinical Pharmacokinetics. Furthermore, she is involved in key committees related to alternative sampling and infections within IATDMCT, and is an NWO VIDI member.

Beyond her administrative and advisory roles, she chairs the Young Investigator Grant Committee and leads the expert team on Knowledge Security at Erasmus MC. With over 250 publications on PK/PD, Therapeutic Drug Monitoring, and Toxicology to her name, she has made significant contributions to the field. As the principal investigator of several studies on model-based dosing, TDM, and PK in antibiotics and psychoactive drugs—backed by over €3 million in funding—her research focuses on alternative matrices, drug pharmacokinetics and pharmacodynamics in special populations, and toxicology during pregnancy.

At Erasmus MC, she leads a vibrant research group of 20–30 professionals, including PhD students, postdoctoral researchers, assistant and associate professors. This multidisciplinary team, composed of physicians, pharmacists, and experts in biopharmaceutical and mathematical sciences, collaborates to advance personalized dosing approaches that optimize patient care and drug efficacy.